血漿の世界市場2020-2031

◆英語タイトル:GLOBAL BLOOD PLASMA MARKET FORECAST 2020-2028
◆商品コード:INK20MY020
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:255
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算¥472,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは血漿の世界市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、伝達方法別(輸液、ゲル、スプレー、生体医療シーラント)分析、障害別(免疫不全症、低ガンマグロブリン血症、血友病、フォン・ヴィレブランド病、その他)分析、血漿誘導体別(免疫グロブリン、静脈内免疫グロブリン、皮下免疫グロブリン、その他)分析、治療適応別(神経内科、免疫学、腫瘍学、移植、その他)分析、エンドユーザー別(病院及びクリニック、研究所、学術機関)分析、地域別分析、企業情報などの情報をお届けいたします。
・調査範囲・手法
・エグゼクティブサマリー
・市場動向
・主要分析
・血漿世界市場:伝達方法別(輸液、ゲル、スプレー、生体医療シーラント)
・血漿世界市場:障害別(免疫不全症、低ガンマグロブリン血症、血友病、フォン・ヴィレブランド病、その他)
・血漿世界市場:血漿誘導体別(免疫グロブリン、静脈内免疫グロブリン、皮下免疫グロブリン、その他)
・血漿世界市場:治療適応別(神経内科、免疫学、腫瘍学、移植、その他)
・血漿世界市場:エンドユーザー別(病院及びクリニック、研究所、学術機関)
・地域別分析
・企業情報
【レポートの概要】

KEY FINDINGS
The global blood plasma market is projected to register a CAGR of 6.24% during the forecast period, 2020-2028. The eminent drivers of market growth are the increasing patient pool for hemophilia treatment, the rising geriatric population, the increasing occurrence of sports injuries, and the growing usage of albumin in therapeutic areas.

MARKET INSIGHTS
Plasma is essential for the regulation of body functions. Blood Plasma comprises of several components that are useful, like coagulation factors, immunoglobulin, protease inhibitors, and albumin. It forms an essential part of therapeutic treatment for several therapies for its potential in combating several chronic diseases like leukemia and hemophilia. Immunodeficiency is a major factor responsible for severe infections, and has become a significant concern in several parts of the world. The new product launches and enhancements are augmenting the demand for blood plasma products in the market. At the same time, the expenses involved in such therapies, and the risk of blood-borne disease transmission, are the factors estimated to impede the growth of the market. The market faces challenges like a lack of a safe blood donor base, along with the shortage of plasma fractionation facilities. The competitive nature of the market is highly intense, and the market has the presence of a limited number of players.

MARKET INSIGHTS
The global blood plasma market is segregated geographically into Europe, North America, Asia Pacific, and the rest of the world, for further analysis. The North American region held the largest market share in 2019. Inkwood Research estimates the region to continue the trend until the end of the forecast period. The region is considered to be the epicenter for blood plasma therapy research and development activities, which is incorporated into various treatment methods in the region.

COMPETITIVE INSIGHTS
Some of the renowned companies registering their presence in the market include, Baxter International, Biotest AG, Takeda Pharmaceutical Company, Fusion Health Care, Arthrex, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. WIDESPREAD ACCEPTANCE OF IMMUNOGLOBULIN-BASED THERAPIES
3.2.2. GROWING USAGE OF ALBUMIN IN OTHER THERAPEUTIC AREAS
3.2.3. GROWING GERIATRIC POPULATION
3.2.4. RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
3.2.5. INCREASE IN THE PATIENT POOL FOR HEMOPHILIA TREATMENT
3.2.6. RISE IN OCCURRENCE OF SPORTS INJURIES
3.3. KEY RESTRAINTS
3.3.1. INCREASING USAGE OF RECOMBINANT PLASMA PRODUCTS IN THERAPEUTIC TREATMENTS
3.3.2. HIGH COSTS OF BLOOD PLASMA TREATMENTS
3.3.3. ADVERSE REACTIONS ASSOCIATED WITH POST-TRANSFUSION
3.3.4. SPREAD OF PATHOGENIC CONTAMINANTS
3.3.5. HIGH REGULATIONS IN THE MARKET
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCES ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. PLASMA THERAPEUTICS REGULATION
4.3. CLINICAL GUIDELINES
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY INVESTMENT INSIGHTS
5. MARKET BY MODE OF DELIVERY
5.1. INFUSION SOLUTIONS
5.2. GELS
5.3. SPRAYS
5.4. BIOMEDICAL SEALANTS
6. MARKET BY DISORDER
6.1. IMMUNODEFICIENCY DISEASE
6.2. HYPOGAMMAGLOBULINEMIA
6.3. HEMOPHILIA
6.4. VON WILLEBRAND DISEASE (VWD)
6.5. OTHER DISORDERS
7. MARKET BY BLOOD PLASMA DERIVATIVES
7.1. IMMUNOGLOBULIN
7.1.1. INTRAVENOUS IMMUNOGLOBULIN
7.1.2. SUBCUTANEOUS IMMUNOGLOBULIN
7.1.3. OTHER IMMUNOGLOBULIN TYPES
7.2. ALBUMIN
7.3. HYPERIMMUNE
7.4. COAGULATION FACTOR CONCENTRATES
7.5. OTHER PLASMA FRACTIONATION PRODUCTS
8. MARKET BY THERAPEUTIC INDICATION
8.1. NEUROLOGY
8.2. IMMUNOLOGY
8.3. ONCOLOGY
8.4. TRANSPLANTATION
8.5. HEMATOLOGY
8.6. RHEUMATOLOGY
8.7. PULMONOLOGY
8.8. OTHER THERAPEUTIC INDICATION
9. MARKET BY END-USER
9.1. HOSPITALS AND CLINICS
9.2. RESEARCH LABORATORIES
9.3. ACADEMIC INSTITUTIONS
10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. THE UNITED STATES
10.1.2. CANADA
10.2. EUROPE
10.2.1. THE UNITED KINGDOM
10.2.2. GERMANY
10.2.3. FRANCE
10.2.4. ITALY
10.2.5. RUSSIA
10.2.6. BELGIUM
10.2.7. POLAND
10.2.8. REST OF EUROPE
10.3. ASIA PACIFIC
10.3.1. JAPAN
10.3.2. CHINA
10.3.3. AUSTRALIA & NEW ZEALAND
10.3.4. INDIA
10.3.5. SOUTH KOREA
10.3.6. THAILAND
10.3.7. INDONESIA
10.3.8. VIETNAM
10.3.9. REST OF ASIA PACIFIC
10.4. REST OF WORLD
10.4.1. LATIN AMERICA
10.4.2. MIDDLE EAST & AFRICA
11. COMPANY PROFILES
11.1. ADMA BIOLOGICS
11.2. ARTHREX
11.3. BIO PRODUCTS LABORATORY
11.4. BAXTER INTERNATIONAL
11.5. BIOTEST AG
11.6. CERUS CORPORATION (CERUS)
11.7. CHINA BIOLOGIC PRODUCTS
11.8. CSL LIMITED
11.9. FUSION HEALTH CARE
11.10. GREEN CROSS HOLDINGS CORPORATION
11.11. GRIFOLS
11.12. LFB
11.13. OCTAPHARMA
11.14. TAKEDA PHARMACEUTICAL COMPANY
11.15. KEDRION BIOPHARMA INC



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[血漿の世界市場2020-2031]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆